With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

Glucagon-like peptide-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With the potential to significantly change consumer eating habits, they are ...

For patients with type 2 diabetes, glucagon-like peptide-1 receptor agonist use is associated with a reduced risk for developing hematologic cancers compared with insulin and metformin use.

After adjustment for confounding variables, researchers found no increased suicide risk for GLP-1 receptor agonists versus DPP-4 inhibitors or SGLT-2 inhibitors.

such as with the mitochondrial uncoupler dinitrophenol or beta-adrenergic activation, these approaches have faced safety and efficacy challenges. Recent advances in glucagon receptor (GCGR ...

SSTR 2 is a highly expressed receptor in human and rodent pancreatic alpha cells thought to block glucagon release. Next, Yeung wanted to determine how this toxin affected glucagon secretion in rodent ...

Feb. 5, 2025 /PRNewswire/ -- The American College of Clinical Pharmacology ® (ACCP) published a recent Position Paper entitled "Ensuring the Appropriate Use of Glucagon-Like Peptide-1 Receptor ...

Viking's clinical programs include VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1 ... small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and ...